Chinese medical device makers push into Europe as anti-corruption squeeze bites at home

Facing anti-corruption policies and profit squeezing at home, Chinese innovative medical device companies are accelerating their push into the European market despite mounting cross-border trade…

Government-backed hospital purchases of medical devices in China fell about 12 per cent year on year in the first five months of 2026, partly weighed down by “a new anti-corruption probe into hospitals”, dragging on the revenue of major Chinese medical device makers in the first half, said Linda Shu, head of China healthcare research at HSBC, in a report on July 10.

Public hospitals handled about 84 per cent of all patient visits in China, according to National Health Commission data released last year, making them the dominant buyers of medical equipment.

Among the latest Chinese companies joining the European push was heart medical device maker Jenscare Scientific, headquartered in Ningbo, eastern Zhejiang province, according to a filing with the Hong Kong stock exchange on July 8.

Its LuX-Valve Plus, the second device of its kind worldwide to win approval, has received CE certification under the European Union’s updated Medical Device Regulation, clearing it for sale across the region. The device replaces a damaged tricuspid valve, one of four valves in the human heart, through a vein rather than open-chest surgery.

The firm called the approval a “milestone” in its international strategy.